JULY - 20224CONTENTSIN MY OPINIONLAST WORDPERSPECTIVES ON THE CURRENT LANDSCAPE OF TRANSCATHETER THERAPIES FOR AORTIC AND MITRAL VALVE DISEASE12THE INNOVATION PROCESS: DEVELOPING LIFE SAVING MEDTECH08Janna Parks, Director Operations Quality, Abbott [NYSE:ABT]30THE FUTURE OF MEDTECH LIES IN ADVANCED TECHNOLOGYChad Lussier, Vice President, Client Solutions, Healogics, Inc.STREAMLINING AUB TREATMENT WITH A COMPLETE SUITE OF MINIMALLY INVASIVE DEVICESDave Clapper, President and CEO
< Page 3 | Page 5 >